Dr. O'Shaughnessy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3410 Worth St
Ste 800
Dallas, TX 75246Phone+1 214-370-1000Fax+1 214-370-1060- Is this information wrong?
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
Massachusetts General HospitalResidency, Internal Medicine, 1982 - 1985
Yale School of MedicineClass of 1982
Certifications & Licensure
TX State Medical License 1997 - 2024
IN State Medical License 1995 - 1999
KY State Medical License 1995 - 1999
MD State Medical License 1985 - 1995- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Join now to see all
Clinical Trials
- PhII ICb With/Without Erbitux in MBC Pts Start of enrollment: 2005 Jul 28
- Satraplatin for Patients With Metastatic Breast Cancer (MBC) Start of enrollment: 2005 Nov 01
- A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 29 citationsIpatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity...Nicholas C. Turner, Rebecca Dent, Joyce O'Shaughnessy, Sung-Bae Kim, Steven J. Isakoff, Carlos H. Barrios, Shigehira Saji, Igor Bondarenko, Zbigniew Nowecki, Qinshu Li...> ;Breast Cancer Research and Treatment. 2021 Dec 3
- 11 citationsMatched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter Ansell, Mark A. Watson, Junu Bae, Mathew Cherian, Joyce O'Shaughnessy, Michael Untch, Hope S. Rugo, Jens Huobe...> ;NPJ Breast Cancer. 2021 Nov 11
- 2 citationsMatching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.Peter A. Fasching, Thomas E. Delea, Yen-Shen Lu, Richard De Boer, Sara A. Hurvitz, Aaron Moynahan, David Chandiwana, Brad Lanoue, H. Hu, A. Thuerigen, Joyce O'Shaughnessy> ;Cancer Management and Research. 2021 Nov 1
- Join now to see all
Lectures
- First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 lo...2019 ASCO Annual Meeting - 6/1/2019
- CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone...2019 ASCO Annual Meeting - 6/1/2019
- Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
What Is Inflammatory Breast Cancer? Patient Jennifer Cordts Talks with Dr. Joyce O’ShaughnessyFebruary 28th, 2023- Anti-CDK4/6 in Metastatic Breast Cancer Showed Further Benefits at SABCSJanuary 24th, 2023
- Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast CancerOctober 20th, 2021
- Join now to see all
Hospital Affiliations
Baylor University Medical CenterDallas, Texas
Medical City DallasDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
